financetom
Business
financetom
/
Business
/
Knife River Likely to Exceed 2025 EBITDA Margin Target Without Need for M&A, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Knife River Likely to Exceed 2025 EBITDA Margin Target Without Need for M&A, Oppenheimer Says
Apr 1, 2025 12:31 PM

03:09 PM EDT, 04/01/2025 (MT Newswires) -- Knife River (KNF) can likely exceed its original 20% EBITDA margin target for 2025 without the need for any mergers and acquisitions as the company has not seen any softness outside of normal seasonal weakness, Oppenheimer said in a note emailed Tuesday.

According to the note, the Infrastructure Investment and Jobs Act, or IIJA, and state-level spending remain a tailwind for the business as there's a steady flow of public projects which have not seen any slow down.

Furthermore, with an overwhelming majority of Knife River's contracting business coming from public works, the business line is insulated as it is less sensitive to economic slowdowns, the note said. The contract business can also benefit from pending infrastructure authorization of $939 million in Idaho, according to the note.

In the private construction side, the supplier of construction materials could benefit from data center demand, particularly in Oregon and Wyoming where land is cheap and cold weather helps with cooling, according to Oppenheimer.

"We are more confident in the path to 20%-plus EBITDA margins (vs. 16% in FY24)," Oppenheimer said.

The company reported Q4 results on Feb. 13 and said it was expecting full-year 2025 adjusted EBITDA of $485 million to $535 million, which does not include the impact of any acquisitions including the Strata acquisition.

The firm said it remains bullish on the stock given its "solid fundamentals" and maintained an outperform rating with a $120 price target.

Shares were up 1.7% in recent trading.

Price: 91.71, Change: +1.50, Percent Change: +1.66

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
International, domestic insurers push into catastrophe-hit US property markets
International, domestic insurers push into catastrophe-hit US property markets
Dec 17, 2024
LONDON (Reuters) -International and domestic insurers are pushing into the U.S. market for hard-to-protect homes, charging high premiums and enjoying strong profits after some U.S. firms pulled out. Rising losses from storms, hurricanes and wildfires in recent years have caused some insurers, such as Allstate and State Farm, to cut back cover in catastrophe-hit states like Florida and California. This...
--Tesla Accuses German Union of Sowing Unrest at Gigafactory, Reuters Reports
--Tesla Accuses German Union of Sowing Unrest at Gigafactory, Reuters Reports
Dec 17, 2024
01:05 PM EST, 12/17/2024 (MT Newswires) -- Price: 474.24, Change: +11.22, Percent Change: +2.42 ...
International, domestic insurers push into catastrophe-hit US property markets
International, domestic insurers push into catastrophe-hit US property markets
Dec 17, 2024
* Rising losses from natural disasters see some insurers cut cover in catastrophe-hit states * Homeowner premiums have soared, 50% rise not uncommon, broker says * Lloyd's of London insurance market has stepped in, has biggest market share (Adds comment from Allstate in paragraphs 4-5, updates dateline) By Carolyn Cohn and Noor Zainab Hussain LONDON, Dec 17 (Reuters) - International...
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study
Dec 17, 2024
On Tuesday, Regeneron Pharmaceuticals, Inc. ( REGN ) announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD (aflibercept) Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion (RVO) RVO is a blockage in one of the veins in the retina, the light-sensitive tissue at the back of the eye. Also...
Copyright 2023-2026 - www.financetom.com All Rights Reserved